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B I O C H E M I S T R Y
GADL1 is a multifunctional decarboxylase with  
tissue-specific roles in -alanine and  
carnosine production
Elaheh Mahootchi1, Selina Cannon Homaei1,2, Rune Kleppe2, Ingeborg Winge1, Tor-Arne Hegvik1, 
Roberto Megias-Perez1, Christian Totland3,4, Floriana Mogavero5, Anne Baumann1,  
Jeffrey Colm Glennon5,6, Hrvoje Miletic1,7, Petri Kursula1,8, Jan Haavik1,2*
Carnosine and related -alanine–containing peptides are believed to be important antioxidants, pH buffers, and 
neuromodulators. However, their biosynthetic routes and therapeutic potential are still being debated. This study 
describes the first animal model lacking the enzyme glutamic acid decarboxylase–like 1 (GADL1). We show that 
Gadl1−/− mice are deficient in -alanine, carnosine, and anserine, particularly in the olfactory bulb, cerebral cortex, 
and skeletal muscle. Gadl1−/− mice also exhibited decreased anxiety, increased levels of oxidative stress markers, 
alterations in energy and lipid metabolism, and age-related changes. Examination of the GADL1 active site indi-
cated that the enzyme may have multiple physiological substrates, including aspartate and cysteine sulfinic acid. 
Human genetic studies show strong associations of the GADL1 locus with plasma levels of carnosine, subjective 
well-being, and muscle strength. Together, this shows the multifaceted and organ-specific roles of carnosine pep-
tides and establishes Gadl1 knockout mice as a versatile model to explore carnosine biology and its therapeutic 
potential.
INTRODUCTION
Carnosine (-alanyl-l-histidine) is one of several dipeptides of 
-alanine and histidine that are found in high concentrations in ver-
tebrate tissues, particularly in the brain and skeletal muscle (SKM) 
tissues. In humans, carnosine and acetylcarnosine are most abundant. 
In contrast, many animals mainly synthesize the related -alanine–
containing peptides anserine or ophidine/balenine through methyl-
ation of the imidazole moiety of carnosine in the 1 or 3 position 
(1, 2). Here, we refer to this family of related peptides as “carnosine 
peptides.”
Carnosine peptides may have multiple biological functions, in-
cluding calcium regulation, pH buffering, metal chelation, and anti-
oxidant effects (1). -Alanine, as well as its dipeptide derivatives, may 
also be neurotransmitters or neuromodulators in the central nervous 
system, especially in olfactory bulb (OB). In mammals, including 
mice, only two tissues have carnosine concentrations in the millimolar 
range, i.e., SKM and OB (1, 3). Various disorders and dysfunctions 
have been linked to alterations in -alanine and carnosine metabolism. 
In -alaninemia and carnosinemia, decreased degradation of these 
compounds is associated with neurological symptoms (4, 5). Con-
versely, it has been suggested that some age-related and neurological 
diseases, e.g., Alzheimer’s disease, Parkinson’s disease, multiple sclerosis 
(MS), and cancer, as well as diabetes complications, may benefit from 
carnosine supplementation (6).
-Alanine supplementation increases carnosine content and im-
proves contractility and muscle performance of human and rodent 
SKM, especially during short exercise intervals (7, 8). These findings 
have led to the widespread use of dietary -alanine supplements, par-
ticularly among athletes and soldiers (9). -Alanine and carnosine 
dietary supplementation have also shown some promising effects in 
the treatment of depression, anxiety, and autism symptoms in hu-
mans (10) and animal models (11, 12).
As most carnosine peptides are hydrolyzed after oral ingestion, 
either in enterocytes or in the blood circulation, the body mainly 
depends on de novo synthesis of these peptides. Dietary supplemen-
tation has side effects but requires a daily intake of several grams to 
increase muscle -alanine and carnosine content and physical per-
formance (13). The lack of suitable model systems and the need to 
supply pharmacological quantities of carnosine peptides have caused 
some uncertainty regarding the mechanisms of action and safety of 
these compounds. A more stable, synthetic analog of carnosine, car-
nosinol, was recently shown to protect against metabolic dysregula-
tion and oxidative damage (14).
Synthesis of -alanine appears to be a rate-limiting factor for 
carnosine peptide levels in mammals (15). In a large genome-wide 
association (GWA) study on plasma metabolites, it was estimated 
that 86% of the variation in carnosine levels could be attributed to 
genetic factors, making this peptide the most heritable metabolite 
among all compounds examined (16). Still, uncertainty remains re-
garding the identity of the genes and proteins involved in its synthesis. 
Carnosine synthase 1 (encoded by CARNS1) produces carnosine from 
-alanine and histidine and homocarnosine from -aminobutyric 
acid (GABA) and histidine. In animal tissues, -alanine may be pro-
duced by reductive degradation of uracil (17). In contrast, some bacteria 
produce -alanine by -decarboxylation of aspartic acid (Asp), cat-
alyzed by aspartate decarboxylase with the aid of a covalently bound 
pyruvoyl cofactor (18). In insects, an analogous vitamin B6 [pyridoxal 
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phosphate (PLP)]–dependent enzyme l-aspartate--decarboxylase 
has evolved by convergent evolution (19). The formation of car-
nosine in the mouse SKM is dependent on vitamin B6, implicating 
a PLP-dependent enzyme in its synthesis in animals as well (20).
On the basis of its sequence similarity to glutamic acid decarboxylase 
(GAD), the PLP-dependent enzyme GAD-like protein 1 (GADL1; 
acidic amino acid decarboxylase) has been assigned a possible role 
in GABA synthesis and to be associated with lithium response in 
bipolar patients (21). Although this genetic association was not rep-
licated in other clinical samples (22), these findings have triggered 
interest in the in vivo investigation of GADL1 function and bio-
chemical properties. As cysteine sulfinic acid (CSA) is a substrate of 
GADL1, it was suggested that GADL1 is involved in the biosynthesis 
of hypotaurine and taurine (23). However, it has also been reported 
that purified human (23) and mouse (24) GADL1 can synthesize 
-alanine from Asp, although at very low rates in vitro. This is con-
sistent with recent crystallographic studies, showing that GADL1 
shares structural features with both CSA decarboxylase (CSAD) and 
Asp decarboxylase (25). Moreover, a human genetic association study 
demonstrated that single-nucleotide polymorphisms (SNPs) in the 
GADL1 intron are strongly associated with blood levels of acetyl-
carnosine (26) that, in turn, are strongly correlated with carnosine 
levels (2). On the basis of these observations, we hypothesized that 
GADL1 could be involved in -alanine and carnosine production in 
mammalian tissues.
Here, we describe the first Gadl1 knockout (KO) mouse model 
and demonstrate an organ-specific role of GADL1 in the biosynthesis 
of carnosine peptides and protection against oxidative stress, par-
ticularly in the OB and SKM. To understand the substrate specific-
ity of GADL1, we compared the three-dimensional (3D) structures 
of mouse GADL1 and related enzymes. Last, we investigate the as-
sociation between common genetic variants in enzymes and trans-
porters involved in carnosine homeostasis with multiple human 
traits and diseases and present an initial behavioral characterization 
of the Gadl1 KO mouse.
RESULTS
Mice lacking GADL1 show age-related changes
Gadl1−/− (null) mice were generated using Cre/loxP technology. Be-
cause of the proximity of the Gadl1 gene to the Tgfbr2 gene that 
encodes a receptor with possible effects on growth and survival, we 
applied a conservative knocking out strategy, where only Gadl1 exon 7, 
coding for part of the PLP-binding active site of GADL1, was deleted 
(Fig. 1A). Gadl1+/+, Gadl1+/−, and Gadl1−/− mice were successfully 
generated in the expected Mendelian ratios by breeding from Gadl1+/− 
mice. We observed no obvious physical abnormalities. Overall ac-
tivity and feeding behavior, as well as initial growth curves, were 
similar across all genotypes. However, after 30 weeks of age, com-
pared to Gadl1+/+ mice, female and male Gadl1−/− mice exhibited 
relative growth retardation, compatible with age-related and possi-
ble degenerative changes (Fig. 1, B and C).
Genomic DNA sequencing and Southern blot analyses confirmed 
the elimination of exon 7 (Fig. 1, D and E). However, quantification 
of Gadl1 mRNA from SKM and OB revealed that some Gadl1 mRNA 
species could be detected across all genotypes. RNA sequencing 
showed that Gadl1−/− mice lacked Gadl1 exons 7 and 8. This was con-
firmed using quantitative reverse transcription polymerase chain re-
action (qRT-PCR) of individual exons (see below). Bioinformatic 
analyses showed that the deletion of exons 7 and 8 was coupled to the 
generation of a new RNA splicing site in the mutated mice (fig. S1).
Western blotting confirmed that GADL1 protein was present in 
Gadl1+/+ and Gadl1+/− but not in Gadl1−/− mice. In OB extracted 
from Gadl1+/+ mice, GADL1 appeared as a wide band, with an esti-
mated molecular mass of 55 to 59 kDa (Fig. 1F). This corresponds 
to several predicted protein variants with 502 to 550 amino acids 
(24). Since exons 7 and 8 encode amino acids involved in cofactor 
binding, GADL1 lacking these amino acids was predicted to be en-
zymatically inactive. This was confirmed by expressing the protein 
lacking exons 7 and 8 in Escherichia coli and comparing it to the 
full-length protein (Fig. 1G and fig. S2). The mutant protein yield 
was only 17% compared to that of the full-length protein. Further-
more, the mutant protein was completely devoid of enzyme activity 
(Fig. 1H). This demonstrated that the elimination of gene function 
was successful and that the Gadl1−/− mice did not have any residual 
GADL1 enzyme activity.
Elimination of Gadl1 alters the OB transcriptome
To determine the effects of GADL1 depletion on gene expression, we 
sequenced and compared OB mRNA levels from Gadl1+/+, Gadl1+/−, and 
Gadl1−/− mice (Fig. 1, I to K). The top 25 up- and down-regulated 
genes (log2 fold change either less than −1 or greater than +1 and 
P ≤ 0.05) are shown in table S1 and fig. S3. Pathway enrichment 
analysis showed that the strongest affected group of genes is involved 
in drug metabolism [Kyoto Encyclopedia of Genes and Genomes 
(KEGG pathway mmu00983; P = 0.00016, q = 0.014] (Table 1) (27). 
This pathway includes the Upb1 gene (-ureidopropionase 1), a tran-
script with a twofold increase in Gadl1−/− mice (P = 0.0154). UPB1 
catalyzes the last step in the formation of -alanine from pyrimidines. 
This is consistent with a compensatory mechanism for maintaining 
-alanine synthesis in the absence of GADL1. Moreover, in OB of 
Gadl1−/− mice, we observed increased transcript levels of multiple iso-
forms of carboxylesterase 1, cytochrome P450, and myeloperoxidase. 
A gene ontology (GO) pathway analysis (27, 28) of up- or down- 
regulated genes (log2 fold change either less than −1 or greater than 
+1 and P ≤ 0.05) showed statistical significant alterations in 24 different 
biological processes, where the most significant alteration involves drug 
catabolism (GO:0042737; P = 2.43 × 10−7, q = 0.0007). Furthermore, 
biological processes involving circadian rhythms and sleep cycles seemed 
to be altered. Dopamine receptors (Drd1 to Drd3) and adenosine A2a 
receptor (Adora2a) were the most consistently recurring genes throughout 
the GO analysis (table S2). It has been reported that the release of 
glutamate from terminals of carnosine containing olfactory neurons 
in OB glomeruli is modified by dopamine receptors (29). It is possible 
that the elimination of GADL1 and carnosine depletion also affected the 
expression of these modulatory transmitter receptors in the OB. Wu et al. 
(30) recently reported that GADL1 overexpression inhibited Potassium 
channel tetramerization domain containing 12 (KCTD12) expression. 
However, a comparison of Gadl1−/− and Gadl1+/+ mice showed that RNA 
levels of KCTD12 were unaffected by the deletion of Gadl1 (P = 0.62).
Deletion of Gadl1 perturbs carnosine metabolism
To explore the biological function(s) of GADL1, we performed un-
targeted liquid chromatography–mass spectrometry (LC-MS) me-
tabolomic analyses of eight different tissues from 20 Gadl1+/+ mice 
and 21 Gadl1−/− mice that were matched across genotype and sex 
(Fig. 2). The number of identifiable metabolites varied between 541 
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Fig. 1. Generation and characterization of GADL1 KO mice. (A) Targeting strategy for knocking out exon (Ex) 7 of the mouse Gadl1 locus on chromosome 9. Gadl1 
coding sequences (hatched rectangles), noncoding exon portions (blue rectangle), and chromosome sequences (orange rectangles) are represented. The neomycin 
(neo)–positive selection cassette is indicated between loxP sites (blue triangles) and Flippase recognition target (FRT) sites (plum triangles). (B and C) Growth curves of 
Gadl1+/+ (n = 4 to 34) and Gadl1−/− mice (n = 4 to 40), presented as means ± SD. Differences between genotypes were significant; P = 0.0008 (64 weeks) and P = 0.0005 
(70 weeks) for males and P = 0.0084 (90 weeks) and P = 0.0001 (94 weeks) for females, respectively. (D) Southern blot analysis of genomic DNA from Gadl1+/+ and Gadl1−/−. 
(E) Genotyping of the offspring from intercrosses of Gadl1+/− mice by polymerase chain reaction (PCR). The DNA band at 166 base pair (bp) is the KO allele (primer 3), while 
bands at 330 bp (primer 2 and 3) and 750 bp (primer 1) are the wild-type alleles. (F) Representative Western blots of OB samples from Gadl1+/+ and Gadl1−/− mice (34 weeks 
old, female) using anti-GADL1 antibody. Positive control was recombinant His-tagged GADL1 (2 ng; lane 1). (G) Western blot of recombinant His-tagged truncated 
Gadl1+/+ and Gadl1−/−. (H) Enzyme activity toward CSA of recombinant His-tagged truncated Gadl1+/+ and Gadl1−/−; P < 0.001. (I to K). RNA expression levels (volcano 
plots) in OB tissue. (I) Gadl1+/+-to-Gadl1+/− ratio, (J) Gadl1+/+-to-Gadl1−/− ratio, and (K) Gadl1−/−-to-Gadl1+/−ratio. (L to N) Quantitative reverse transcription PCR (qRT-PCR) 
analysis of normalized mRNA expression in OB, brain, SKM, and liver tissues from 35-week-old female Gadl1+/+ (gray), Gadl1+/− (blue), and Gadl1−/− (red) mice for (L) Gadl1 
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serum, and kidney. Partial least squares–discriminant analyses (PLS-
DA) were used to evaluate metabolic differences between Gadl1+/+ 
and Gadl1−/− mice. This allowed identification of suitable markers 
responsible for the metabolic differences by variable important pro-
jection (VIP) scores.
The metabolic features with VIP scores higher than 2, responsi-
ble for the separation in each tissue, are depicted in Fig. 2 (A to D). 
Carnosine peptides showed the strongest difference between the geno-
types in the OB and the cerebral cortex (Fig. 2E). Carnosine was also 
among the most strongly affected metabolites in SKM but not in the 
liver (Fig. 2E). Although GADL1 has been postulated to synthesize 
GABA from glutamate, the levels of GABA and glutamate in Gadl1+/+ 
and Gadl1−/− mice were similar in all tissues examined (fold differ-
ence of 0.88 to 1.15 for glutamate and 0.96 to 1.53 for GABA; P > 
0.05). Gadl1−/− mice had significantly reduced levels of -alanine in OB 
but nonsignificant reduction in the cerebral cortex and SKM and unaltered 
levels in the liver. In contrast, carnosine, acetylcarnosine, and anserine 
were significantly depleted in brain and SKM tissues. A nonsignificant 
reduction (~10%) of -alanine and carnosine peptides was observed in 
the serum and whole blood (fig. S4A), as well as in the kidney, cerebel-
lum, and heart. Together, this is consistent with the observed tissue 
distribution of GADL1 and demonstrates its key role in the metabolic 
pathway of -alanine and carnosine peptides.
High-resolution magic angle spinning nuclear magnetic 
resonance spectroscopy confirms the depletion of carnosine 
in Gadl1−/− mice
To determine the role of GADL1 on carnosine content in intact tis-
sue, we used fresh OB tissue where we found the highest expression 
GADL1. We performed high-resolution magic angle spinning (MAS) 
1H–nuclear magnetic resonance (NMR) spectroscopy on OB from 









KEGG ID mmu00983 mmu00830 mmu00980 mmu00380
Gene ID Abbr. Name Log2 fold P value 0.00016 0.00022 0.00025 0.00045
14869 Gstp2 Glutathione S-transferase, pi 2 −4.2819 0.0374
13897 Ces1e Carboxylesterase 1E 4.9087 0.0040
104158 Ces1d Carboxylesterase 1D 3.8723 0.0131
234564 Ces1f Carboxylesterase 1F 2.6056 0.0193






103149 Upb1 -Ureidopropionase 1.0121 0.0154
27400 Hsd17b6 Hydroxysteroid (17-) 
dehydrogenase 6
4.0829 0.0103
13087 Cyp2a5 Cytochrome P450 2A5 3.9985 0.0129
213043 Aox2 Aldehyde oxidase 2 3.4965 0.0260
13086 Cyp2a4 Cytochrome P450 2A4 3.1973 0.0157
13076 Cyp1a1 Cytochrome P450 1A1 3.0800 0.0010
11522 Adh1 Alcohol dehydrogenase 1, class 1 1.7208 0.0144
13107 Cyp2f2 Cytochrome P450 2F2 2.9664 0.0024
12409 Cbr2 Carbonyl reductase 2 1.2641 0.0012
11298 Aanat Arylalkylamine N-acetyltransferase −1.3632 0.0008
15930 Ido1 Indoleamine 2,3-dioxygenase 1 2.4039 0.0192
21743 Inmt Indolethylamine N-methyltransferase 1.2043 0.0401
Table 2. Male and female mice used in the metabolomic study.  
Genotype Sex Number (n) Age 
(weeks ± SD)
Gadl1+/+ Female 11 14.64 ± 7.85
Gadl1−/− Female 11 14.27 ± 7.85
Gadl1+/+ Male 9 8.88 ± 3.98
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Fig. 2. Tissue-specific effects on metabolite levels in Gadl1−/−mice. (A to D) Top significant features of metabolites based on VIP scores of >2 of component 1 of PLS-DA. 
Untargeted metabolic profiling of (A) cerebral cortex, (B) OB, (C) SKM, and (D) liver tissue samples from Gadl1+/+ (n = 20) and Gadl1−/− (n = 21) mice. WT, wild-type. (E) The 
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Gadl1+/+ (n = 4), Gadl1+/− (n = 3), and Gadl1−/− (n = 3) mice. Char-
acteristic features of carnosine (Fig. 3A) could be identified in the 
aromatic regions of the spectrum, in accordance with the quantifi-
cation in tissue extracts (Fig. 3B). Compared to Gadl1+/+, Gadl1+/−, 
and Gadl1−/− mice had 34 and 70% (P = 0.0056) reduced carnosine 
content in the OB (Fig. 3C). To our knowledge, this is the first demon-
stration of carnosine measurement in intact brain tissue, also estab-
lishing MAS NMR spectroscopy as a fast and convenient way to 
determine carnosine in this tissue. Furthermore, we performed brain 
magnetic resonance imaging (MRI) on 94-week-old female Gadl1+/+, 
Gadl1+/−, and Gadl1−/− mice. There were no significant differences 
in the brain morphology of Gadl1 genotypes (Fig. 3, E to F).
Substrate specificity of GADL1
Many PLP-dependent enzymes have multiple substrates (31). To ex-
plore whether the divergent metabolic changes observed in Gadl1−/− 
mice could be secondary to changes in -alanine levels or were due 
to the parallel chemical conversion of multiple substrates by GADL1, 
we solved the crystal structure of mouse GADL1 (25). The structure 
of the closely related CSAD has been solved earlier but not published 
[Protein Data Bank (PDB) entry 2JIS]. With available crystal struc-
tures of GADL1, CSAD, and GAD (32), it is possible to identify 
determinants of substrate specificity in these acidic amino acid de-
carboxylases. GADL1 and CSAD have different, although slightly 
overlapping, physiological functions (24). GADL1, through the 
conversion of Asp to -alanine, is important in carnosine peptide 
biosynthesis, while CSAD catalyzes the major pathway in taurine syn-
thesis, using CSA as substrate. Despite similar chemical structures of 
the two substrates (Fig. 3G), these two highly similar enzymes can 
distinguish between them. Both Asp and CSA are smaller than Glu 
(Fig. 3H), explaining the inability of GADL1 and CSAD to function 
as glutamate decarboxylases (Fig. 3I). The carboxyl group in Asp is 
planar, while the sulfinic acid moiety of CSA is tetrahedral and has 
slightly longer bonds; effectively, CSA is slightly larger and can, per-
haps, more specifically accommodate to a binding site due to its 
shape and charge.
As the chemical reaction catalyzed by the enzymes is identical, 
we can assume that the reactive groups bind in an identical manner, 
and the differences lie in recognizing the side chain of the substrate. 
GAD uses Glu as a substrate, while GADL1 acts on Asp, indicating 
that side-chain length is one determinant of productive binding. For 
binding a negatively charged side chain in the specificity pocket, one 
expects to find positive charge potential in the form of amino groups. 
For GAD, these interactions can be conceived; two backbone NH 
groups and a water molecule coordinated by a conserved His resi-
due coordinate the side-chain carboxyl group in the model of the 
substrate complex, together with a Ser side chain. How is GADL1 
different? The major difference is the substitution of this Ser with a 
Tyr residue (Fig. 3I), effectively making the binding cavity smaller. 
Interactions with the peptide backbone and the His-water unit are 
likely conserved for Asp binding to GADL1. The specificity pocket 
contains a Tyr (GADL1) or Phe (CSAD) residue, and the slightly 
different conformations of these residues are enough to cause this 
difference in substrate specificity.
Tissue-specific effects of GADL1 on the synthesis of taurine 
and its derivatives
On the basis of the ability of purified GADL1 to produce hypotaurine 
from CSA, it has been suggested that the primary biological func-
tion of GADL1 may be in taurine synthesis (23). However, the con-
centrations of the substrates and products in taurine synthesis were 
unaltered in the Gadl1−/− mice in the brain, OB, and liver. In con-
trast, levels of taurine derivatives were moderately reduced in SKM 
in Gadl1−/− (fig. S4). This is consistent with the observations that 
taurine mainly is synthesized by other routes, such as by CSAD (33), 
and our previous finding that CSAD is expressed in low amounts in 
SKM (24). In all tissues examined, CSAD protein has been reported 
to be more abundant than GADL1, and purified CSAD has a 5- to 
35-fold higher specificity constant for decarboxylation of CSA than 
GADL1 (24). Moreover, as shown here, the qRT-PCR analysis showed 
that the levels of Csad mRNA were at least 10-fold higher than levels 
of Gadl1 and were unaffected by the deletion of Gadl1 exons (Fig. 2N). 
Thus, we conclude that in organs with a high content of CSAD, GADL1 
has a minor role in taurine synthesis. In the absence of CSAD, levels 
of taurine in the mouse plasma, liver, and brain decreased by 70 to 
90%, with the largest decrease in the liver and the smallest in the 
brain (33). This remaining taurine biosynthetic capacity has been 
attributed to an alternative biosynthetic route of taurine catalyzed 
by cysteamine dioxygenase from cysteamine, generated from coen-
zyme A (34). However, our results indicate that GADL1 has a small 
taurine biosynthetic capacity in vivo that may contribute to the over-
all production of taurine.
Oxidative stress markers
Several lines of evidence support a role of carnosine peptides in 
protection against oxidative stress (1, 35). To investigate the role 
of GADL1 in antioxidant defense, we compared levels of oxidative 
stress markers in Gadl1+/+ and Gadl1−/− mice. Gadl1−/− mice had 
increased levels of oxidative stress markers, including methionine sulf-
oxide and -glutamyl peptides. These alterations are compatible with 
elevated glutathione synthesis and consistent with elevated oxidative 
stress. Some oxidative stress markers were strongly increased even in 
tissues with a moderate decrease in carnosine peptides, such as the 
liver. We also compared tissue levels of the antioxidant enzymes super-
oxide dismutase 1 (SOD1) (CuZnSOD), SOD2 (MnSOD), and gluta-
thione reductase (GSR) in Gadl1+/+ and Gadl1−/− mice (OB, cerebral 
cortex, and SKM) using Western blotting (Fig. 4). Unexpectedly, the 
most obvious difference was detected in the OB where the Gadl1−/− 
mice had a threefold increase in GSR levels (P = 0.0145) (Fig. 4A).
In contrast to carnosine and anserine, that were reduced in mul-
tiple tissues, levels of homocarnosine were significantly increased in 
the OB of Gadl1−/− mice (Fig. 2E). Several other metabolites related 
to -alanine synthesis were also altered (fig. S4, G, I, and J).
Gadl1−/− mice had also increased levels of many lipid species, in-
cluding sphingolipids, with the strongest effects in OB (Fig. 2, A to D, 
and fig. S4K). Notably, complex sphingolipids accumulate under in-
flammation and oxidative stress, conditions that Gadl1−/− mice seem 
more susceptible to. Moreover, sphingolipids may alter muscle con-
tractility (36).
Animal behavior and tissue morphology
To examine the effects of Gadl1 deletion on brain function, we tested 
a range of mouse behaviors in Gadl1+/+ (n = 13) and Gadl1−/− (n = 13) 
22-week-old male mice. In the open field, the latency to first enter 
the center was significantly different between genotypes, with Gadl1−/− 
mice taking less time to enter the center (Fig. 5, A to E). However, 
the cumulative time spent in the center of the open field was not sig-
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Fig. 3. 1H-NMR and MRI of mouse tissues and substrate specificity of GADL1.  (A to C) Measurement of carnosine in intact OB tissue. (A) Chemical structure of car-
nosine. ppm, parts per million. (B) MAS 1H-NMR spectra of OB tissue samples from Gadl1+/+, Gadl1+/−, and Gadl1−/− male mice (12 weeks). The two hydrogens of the imid-
azole ring in carnosine are marked a and b. (C) Relative integral based on NMR results, presented as means ± SD. (D to F) MRI of the brain in (D) Gadl1+/+, (E) Gadl1+/−, and 
(F) Gadl1−/− mice. The arrow indicates the OB. (G) Chemical structure comparison of GADL1 substrates CSA, Asp, and Glu. (H) 3D substrate structures to show the size and 
shape differences of Glu compared to CSA and Asp. (I) Active sites of GADL1, GAD, and CSAD and the predicted mode of binding of Glu to GAD. The prediction is based 
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intruder test metrics. Only the difference in attack latency between 
initial testing and retesting 1 day later was significantly different be-
tween genotypes. Both genotypes showed a significant preference for 
the social versus nonsocial cylinder in the three-chamber task (P < 
0.0001), but there was no significant difference between the geno-
types. On this basis, it seems that a reduction of carnosine content in 
the mouse OB (~70%) and cerebral cortex (~40%) may result in the 
Gadl1−/− mice showing increased initiation to enter an exposed area 
(which is indicative of decreased anxiety). However, this should be 
tempered by the observation that the total time spent in the center of 
the open nor differences in the ratio of the time spent on closed versus 
open arms of the elevated plus maze were not different. Further inves-
tigation of any possible anxiolytic effect of Gadl1−/− mice is prudent.
To examine the effects of Gadl1 deletion on organ aging and 
morphology, we compared tissue sections from 33 mice aged 28 to 
96 weeks, equally matched across different sex and genotypes. At 
the microscopic level, SKM, brain, and OB morphologies were not 
affected by the elimination of Gadl1 (fig. S5A).
Common genetic variants in the GADL1 locus are associated 
with multiple human phenotypes
GWA studies (GWASs) have shown associations of the GADL1 lo-
cus with multiple human traits and diseases, including eating disor-
ders (37), kidney functions (38), and several blood metabolites. This 
includes a strong association with levels of acetylcarnosine (P = 8.17 × 
10−21) in the GADL1 locus at an intergenic SNP rs6804368 (13.9 kb 
from GADL1 and 17.9 kb from TGFBR2) (26). The strongest associ-
ation (P = 5.50 × 10−37) has been reported for the response to lithium 
(Li+) in bipolar disorder at an SNP (rs17026688) located in intron 6 
of GADL1 (21). However, these findings were not replicated in other 
clinical samples (24).
To get an overview of genetic associations between human pheno-
types and enzymes in carnosine metabolism, we conducted gene-
based tests using the MAGMA software (39), mainly focusing on 
traits related to oxidative protection and brain functions. We included 
associations of common variants in GADL1 and seven related genes 
(Fig. 5) (40). We limited the search to 21 phenotypes with openly 
available GWAS summary statistics obtained from large samples 
(total number of tests 167; Bonferroni-corrected P value threshold = 
2.99 × 10−4). Table S3 shows an overview of the data used.
GADL1 was associated with serum acetylcarnosine levels (P = 
1.25 × 10−11), kidney function (P = 1.03 × 10−7), and subjective well- 
being (P = 1.22 × 10−4). CARNMT1 was associated with body mass 
index (P = 1.12 × 10−4). CARNS1 was associated with right-hand 
grip strength (muscular strength) (P = 4.98 × 10−5). SLC15A2 was 
associated with kidney function (P = 8.60 × 10−12) In addition, several 
tentative gene-phenotype associations did not pass the Bonferroni- 
corrected threshold for significance. In conclusion, of eight tested 
genes known to be involved in carnosine metabolism, GADL1 and 





Fig. 4. Relative levels of antioxidant enzymes in Gadl1−/− mouse tissues. (A to E) Representative Western blots (B, D, and F) and normalized protein expression levels. 
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The most obvious associations were observed for acetylcarnosine 
levels, muscle strength, kidney function, and general well-being but 
not in a range of neuropsychiatric diseases that have been reported 
to respond to carnosine treatment (Fig. 5, G and F) (14).
DISCUSSION
Carnosine peptides were found in 1900, yet their biological functions 
and biosynthetic routes are still being debated (1). Here, we report 
the first animal model lacking GADL1. We show that these animals 
have low levels of -alanine and carnosine peptides, consistent with a 
key role of GADL1 in their synthesis. This enzyme is analogous to Asp 
decarboxylases previously only found in prokaryotes and insects (23).
Carnosine peptides, except for homocarnosine, were significantly 
depleted in the brain and SKM. In contrast, the reduction was modest 
and nonsignificant in multiple other tissues including the kidney, 
heart, whole blood, and serum. Furthermore, -alanine was only 
reduced significantly in OB. As GADL1 activity was eliminated in 
Gadl1−/− mice, the remaining -alanine and its peptide derivatives 
may be derived either from the diet, by gut bacteria, maternally trans-
ferred from heterozygous mothers used for breeding, or by de novo 
synthesis. Biochemical analyses of the standard plant-based rodent 
diet did confirm low levels of -alanine and carnosine, but we can-
not exclude a possible small dietary contribution from -alanine, 
pantothenic acid (vitamin B5), or carnosine peptides (table S4). It is, 
however, more likely that there are several alternative biosynthetic 
routes for -alanine and that these have different roles in different 
tissues. Thus, in tissues with the highest demands for carnosine syn-
thesis, i.e., SKM, brain, and particularly the OB, we demonstrate a 
critical role of de novo -alanine biosynthesis to maintain its levels, 
as well as compensatory up-regulation of enzymes involved in alter-
native biosynthetic routes. As blood levels of -alanine and carnosine 
A
F
B C D E
G
Fig. 5. Behavioral phenotypes associated with Gadl1−/− mice, carnosine homeostasis and human phenotypes. (A) Three-chamber task: Time spent at each cylinder was 
not different between the genotypes. Both Gadl1+/+ and Gadl1−/− mice prefer the social cylinder, indicating that sociability remains similar. (B) Open field task: The cumu-
lative time spent in the center was not different between the genotypes. On this measure, no antianxiety effect was observed. However, on the latency to enter the center 
(another anxiety measure), Gadl1−/− was quicker to enter the center, which may suggest some anxiolytic effects of the Gadl1−/− phenotype that would require confirma-
tion in additional studies. (C) Open field task: The exploration velocity was not different between the genotypes, indicating that there is no effect on motor function. Similar 
observations were made with the total distance moved data. Together, this suggests no effect of genotype on activity metrics. (D) Elevated plus maze: The ratio of the time 
spent (s) on the open and closed arms was found not to be different between the genotypes. Both genotypes prefer the closed (sheltered arm), suggesting no difference in 
anxiety on this measure. (E) Resident intruder paradigm: The attack latency against an intruder from the first to the fifth day (tests 1 to 5) was not different between the gen-
otypes. Both genotypes attack faster on the second day compared to the first day after which the attack latency remains constant. This suggests no effect of genotype on 
aggression. (F) A summary overview of different pathways involving -alanine. Genes analyzed in this study are marked in blue. (G) Association analyses of genes involved in 
the carnosine metabolism. Asterisk indicates statistical significance after correction for multiple testing. ADHD, Attention deficiency hyperactivity disorder; ALS, Amyotrophic 
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peptides were moderately affected by elimination of GADL1, it seems 
that the muscle and brain are less dependent on uptake of these com-
pounds from the circulation.
Alternative biosynthetic routes may include -alanine synthesis by 
CSAD, which has a relatively low -alanine synthetic specific activity but 
much higher tissue abundance than GADL1 (24), production of -alanine 
from uracil by ureidopropionase 1 [-alanine synthase, UPB1; N-carbamoyl-
- alanine amidohydrolase; (BUP1/UPB1)] (41), or by other enzymes, 
such as -alanine-2-oxoglutarate transaminase (ABAT) or -alanine 
pyruvate transaminase (AGXT2) (20). Our findings contrast earlier 
observations that found no decarboxylation of Asp in rat muscle (23). 
Dietary PLP supplementation significantly increases the concentra-
tions of -alanine and carnosine peptides in the SKM of rats (20). 
As GADL1 is dependent on PLP, this increase may be due to the ac-
tivation of GADL1 by PLP. In contrast, PLP is not required for the 
production of -alanine by UPB1. Our observation of increased Upb1 
transcript levels in the OB of Gadl1−/− mice but unaltered levels of 
Abat and Agxt2 indicates a role UPB1 in maintaining levels of -alanine. 
However, this finding contradicts earlier observations of UPB1 pro-
tein in the rat liver and kidney but not in the brain, lung, SKM, or 
spleen (41).
In contrast to the reduced levels of -alanine, carnosine, anserine, 
and acetylcarnosine, the levels of homocarnosine were increased. 
This is probably the result of a shortage of -alanine precursor and 
carnosine peptides, indicating that the tissue levels of these dipep-
tides may be tightly regulated. Moreover, no significant difference in 
GABA between Gadl1+/+ and Gadl1−/− mice was detected. Together 
with the observations of increased homocarnosine (a GABA-derived 
peptide), this indicates that GADL1, despite its name, does not cata-
lyze the decarboxylation of glutamate to GABA. Figure 5F summa-
rizes the different biosynthetic routes of carnosine peptides, and the 
main enzymes and transporters believed to be involved in this me-
tabolism in mammalian tissues.
As the Gadl1 locus on chromosome 3p24.1-3p23 is close to the 
Tgfbr2 locus (3p24.1) and genetic variants in the vicinity of Gadl1 
influence plasma levels of transforming growth factor– (TGF-) 
receptor type 2 (TGFBR2), the gene-targeting strategy was designed 
to avoid regulatory sequences in this region. This strategy resulted 
in the expression of low amounts of a catalytically inactive and un-
stable partially truncated version of the GADL1 protein, but Tgfbr2 
transcripts were unaltered.
To determine the substrate specificity of GADL1, we previous-
ly expressed the mouse enzyme in bacteria and screened purified 
GADL1 against all proteinogenic amino acids, as well as many other 
putative substrates and inhibitors, demonstrating decarboxylase ac-
tivity against Asp, CSA, and cysteine (24). This substrate profile was 
similar to what Liu et al. (23) observed for the human enzyme. How-
ever, compared to other PLP-dependent decarboxylases, the affinity 
and selectivity were very low for all substrates tested. Liu et al. (23) 
reported that it was impossible to detect GADL1 enzyme activities 
in tissue lysates. Here, we show that, despite its extremely low activ-
ity in vitro, GADL1 is important for -alanine and carnosine pep-
tide synthesis, particularly in the OB, cerebral cortex, and SKM.
Gadl1−/− mice also had decreased levels of taurine and multiple 
taurine derivatives in SKM, indicating that CSA also is a physiolog-
ically relevant substrate. Gadl1−/− mice also showed other biochem-
ical alterations that could be secondary to the depletion of -alanine 
derivatives and antioxidant function or other effects of GADL1 in-
activation. Gadl1 deletion might alter energy metabolism through sev-
eral pathways. In addition to its role in carnosine synthesis, -alanine 
is a component in pantothenic acid (vitamin B5) and coenzyme A, 
an essential cofactor for multiple biochemical pathways, including 
energy metabolism.
The role of GADL1 as a relatively nonspecific decarboxylase of 
low molecular weight acid substrates is consistent with its relatively high 
Michaelis-Menten constant (Km) values and low catalytic efficacy (24). 
Mammalian genomes encode hundreds of PLP-dependent enzymes, 
many of which may catalyze new or unclassified reactions (31). In 
addition, because of their common mechanistic features and similar 
structures, many PLP-dependent enzymes can catalyze multiple bio-
chemical reactions. This promiscuity makes it difficult to define their 
primary biological functions (31). Some enzymes have evolved to have 
multiple physiological substrates. Such a reactivity with multiple sub-
strates may be advantageous for fitness (42). GADL1 may be an ex-
ample of an enzyme with multiple biological activities. Although 
the strongest effect of GADL1 deletion seemed to be a decrease in 
-alanine and carnosine peptides, with the taurine pathway being 
intact, the Gadl1−/− mice also had slightly reduced levels of taurine 
derivatives in SKM, consistent with multiple catalytic functions of 
this enzyme. Similarly, while the accumulation of oxidative stress bio-
markers in Gadl1−/− mice is probably secondary to loss of -alanine 
or carnosine peptides, we cannot exclude that the metabolic changes 
could be caused by other functions of GADL1.
Inspection of the catalytic site of mouse GADL1 shows that it 
might be accessible by different small, acidic, polar substrates. From 
the comparison (Fig. 3I), it can be observed that very minor changes 
in specificity-determining amino acids in the active site vicinity 
may dictate the function of an enzyme at the tissue and organism 
level. These structural features correspond well with the previously 
reported substrate specificity of purified mouse and human GADL1 
(23–25). For a more detailed understanding of the catalytic properties 
of GADL1, as well as its closest homologs, high-resolution structural 
studies with active-site ligands, preferably with the flexible catalytic 
loop visible, will be required.
Both in vitro and in vivo experiments have shown that reactive 
oxygen species can decrease the levels of antioxidant enzymes, such 
as SOD and glutathione peroxidase, and that carnosine supplemen-
tation can restore depleted levels of these enzymes (1). Carnosine 
peptides are considered to be important in protection, e.g., against 
ischemia-related free radical damage (1). However, the protective 
function of carnosine has only been studied in vitro or in animals 
receiving large pharmacological doses of carnosine. Thus, -alanine 
and carnosine dietary supplementation have widespread human use 
and are marketed to protect against oxidative stress (1). However, 
contradictory findings have been reported, and elevated levels of 
-alanine were noted to reduce cellular taurine levels and to be as-
sociated with increased oxidative stress (43) and altered energy me-
tabolism (44). Here, we show that the Gadl1 deletion mice have 
increased levels of oxidative stress biomarkers and altered levels 
of several antioxidant enzymes. These findings establish this mouse 
model as a new tool to study not only -alanine synthesis but also 
carnosine peptide biology and their relationship to oxidative stress 
and diseases.
Deletion of the mouse carnosine transporting dipeptide transporter 
Pept2 (SLC15A) has previously been reported to alter carnosine levels 
in several organs but not as markedly as in the Gadl1−/− mice (45). 
These organ-specific effects indicate that although -alanine and car-
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mainly take up carnosine peptides and their precursors from the 
circulation. Carnosine homeostasis in SKM is regulated by multiple 
nutritional and hormonal stimuli in a complex interplay between 
transporters and enzymes, including CARNS, CNDP2, PHT1, PHT2, 
TauT, PAT1, ABAT, and HDC (Fig. 5F) (40). It was recently reported 
that in the SKM, CARNS1 and GADL1 are rapidly up-regulated upon 
high-intensity exercise, demonstrating the importance of carnosine 
in muscle function and physiological regulation of these enzymes 
(46). The importance of GADL1 in carnosine synthesis is supported 
by human genetic studies showing a strong association of GADL1 
variants with blood levels of carnosine peptides (26). However, the 
tissue levels of carnosine peptides are reflecting levels of not only 
-alanine and histidine and their biosynthetic enzymes but also 
other metabolites and enzymes. Thus, the enzymes and transporters 
involved in carnosine homeostasis are nonspecific and subjected to 
competitive inhibition by alternative substrates, which may differ 
between tissues (Fig. 5) (47).
Since Gadl1−/− mice displayed behavioral changes and -alanine 
and carnosine peptides have been implicated in many different phys-
iological functions and disease states, we performed a gene-based 
analysis of GADL1 and enzymes and transporters directly involved 
in carnosine metabolism. We selected 21 human diseases and traits 
related to oxidative stress and where treatment with carnosine pep-
tides has shown some promising effects (Fig. 5G) (12, 48). In addi-
tion to the strong associations with plasma carnosine peptide levels, 
common variants in the GADL1 locus were associated with subjec-
tive well-being and muscle strength. The association with subjective 
well-being is particularly intriguing. This phenotype is genetically 
related to somatic complaints not only as bodily aches and pains but 
also as low energy, anxiety, and depression, traits that have all been 
shown in animal studies to be related to levels of carnosine peptides 
in the brain and SKM (49). However, for most of the diseases studied, 
we observed no significant associations with genes associated with 
carnosine homeostasis. Still, we cannot exclude possible effects of rare 
genetic variants or a role in other patient groups or populations. The 
behavioral data in the Gadl1−/− mice suggest that the link between 
GADL1 with anxiety is worth exploring further, including the in-
vestigation of differences in sensory processing and alterations in 
fear-related behavior.
Brain metabolomics has revealed large regional differences, with 
particularly large concentration gradients for carnosine (50). How-
ever, it is still a mystery why GADL1 and its carnosine peptide prod-
ucts are so abundant in OB. In zebrafish, high immunoreactivity for 
carnosine and anserine is found in sensory neurons and nonsensory 
cells of the olfactory epithelium, olfactory nerve, and the OB, indi-
cating a specific role of these peptides in sensory organs (51). On the 
basis of the early occurrence of carnosine peptides during embryonic 
development, it has been suggested that these peptides play a role in 
the developing nervous system, specifically in the olfactory and visual 
function (51). Our findings of intact histological architecture and the 
modest behavioral effects of Gadl1 deletion may argue against this 
hypothesis. However, it is also possible that the remaining 10 to 30% 
carnosine peptides are adequate for maintaining these biological ef-
fects, as reported for other neurotrophic factors such as serotonin 
(52). Alternatively, a neuroprotective, antioxidant role of GADL1 and 
carnosine peptides is conceivable. The olfactory epithelium provides 
a direct entry route from the environment to the OB and brain for 
substances that could cause oxidative stress. These substances can 
cause age-related cellular degeneration and olfactory damage, and 
prevention of this damage depends on an intact antioxidant defense 
system. Although baseline GADL1 levels are low, the levels of this 
enzyme may be up-regulated in response to oxidative damage and 
other physiological stressors, as shown in oligodendrocytes obtained 
from a mouse model of amyotrophic lateral sclerosis (53) and in SKM 
upon exercise (46).
CONCLUSIONS
GADL1 is essential for the production of -alanine and carnosine 
peptides, particularly in the brain and SKM. Mice lacking GADL1 
have behavioral changes, increased oxidative stress markers, and age- 
related changes, underscoring the biological importance of these pep-
tides. Common variants in the human GADL1 locus are associated 
with plasma levels of acetylcarnosine, muscle strength, kidney func-
tion, and subjective well-being. Future studies should explore how 
this enzyme is regulated and its involvement in physiological func-
tions, including antioxidant defense mechanisms, and pathological 
states.
MATERIALS
Chemicals in this study were purchased from Sigma-Aldrich if not 
otherwise stated. Probes for the qRT-PCR were from Thermo Fisher 
Scientific, the kits used were from Thermo Fisher Scientific or QIAGEN, 
agarose was from Apollo Scientific, and SDS–polyacrylamide gel elec-
trophoresis (PAGE) gels were from Bio-Rad. O-Phthaldialdehyde 
reagent and 2-mercaptoethanol were from Merck Schuchardt. l- 
Carnosine nitrate salt was used as standard for NMR spectroscopy.
METHODS
Ethical statement
This study was carried out per Norwegian laws and regulations and 
the European Convention for the Protection of Vertebrate Animals 
used for Experimental and Other Scientific Purposes. The protocol 
was approved by the Animal Studies Committee, Norwegian Food 
Safety Authority (Mattilsynet, permit number 9468).
Generation of Gadl1-null mice
Gadl1-null (−) mice were generated by homologous recombination 
in C57BL/6N mice at genOway, Lyon, France. On the basis of the 
Gadl1 complementary DNA (cDNA) sequence NM_028638, the exon/
intron organization of the gene was established. The mouse Gadl1 
gene is located on chromosome 9 and extends over more than 183.6 kilo– 
base pairs (kbp) (sequence map Chr9:115909455-116074347 bp, 
+strand). The mouse Gadl1 locus consists of 20 exons (Fig. 1). ATG 
initiation codons are located in exons 3, and stop codons are located 
in exons 19 and 20. Bioinformatic analysis identified three isoforms 
for GADL1 protein and three predicted other splice variants of the 
Gadl1 gene. In the National Center for Biotechnology Information 
database release 106, four isoforms with predicted 518, 479, 362, and 
502 amino acid residues (NM_028638) were identified. On the basis 
of sequence comparison and x-ray structural data (25), Lys405, Lys333, 
and His219 are predicted to be essential amino acids of the PLP-binding 
region, and Arg494 and Gln120 are essential amino acids of the substrate- 
binding region. Exon 7 is highly conserved and contains the substrate- 
binding residue Gln120. This exon is present in all splice variants. In 
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TGFBR2 (sequence map Chr9:116087695-116175363 bp, −strand). 
This is involved in multiple biological pathways and cells. In addi-
tion, several noncoding genes and pseudogenes are located in this 
region. To minimize the risk of interfering with possible regulatory 
sequences, it was decided to delete only exon 7 in the Gadl1 gene, 
resulting in the deletion of sequences encoding part of the active site 
domain of Gadl1, including Q120 (24). The mouse model was generated 
by homologous recombination in embryonic stem (ES) cells. For this 
purpose, a targeting vector containing regions homologous to the 
genomic Gadl1 sequences was constructed. After its transfection into 
C57BL/6N ES cells, the recombined cell clones were injected into 
blastocysts. Mouse breeding was established with C57BL/6N Flp-deleter 
mice to remove the neomycin cassette. The heterozygous KO colony 
was produced by breeding with C57BL/6N Cre-deleter mice.
Breeding
Heterozygous siblings were mated to produce Gadl1−/− homozygous 
pups. Further breeding and genotyping were performed at the ani-
mal facility at the University of Bergen (Bergen, Norway). Animals 
were group-housed in temperature- and light-controlled vivarium 
(21° ± 1°C; 12:12-hour light/dark artificial circadian rhythm). All 
experiments were conducted with 3- to 96-week-old mice of both 
sexes that were ad libitum fed using standard rodent diets [rat and 
mouse no. 1 (RM1)] during maintenance and RM3 during breeding 
(Scanbur/Special Diets Services, Witham, UK). These diets are plant- 
based. The content of natural amino acids is specified, but the content 
of carnosine peptides is not specified (http://sdsdiets.com/pdfs/RM1-
A-P.pdf). Further analysis is shown in table S4.
Gadl1 mouse genotype determination
DNA was extracted from mice ear samples at 2 weeks of age. Geno-
typing was performed using a multiplex PCR kit (#206143, QIAGEN). 
After initial heat activation at 94°C for 15 min, DNA was denatured 
at 94°C for 30 s, annealed at 60°C for 1.30 min, and extended at 72°C 
for 1.30 min. This cycle was repeated 25 times. DNA was extended 
for an additional 30 min after the last cycle. PCR products were an-
alyzed using 2% agarose gel electrophoresis. The PCR product size 
was measured to 166 bp in the Gadl1−/− mice and 330 and 750 bp in 
the Gadl1+/+ mice. All three base pair sizes were measured in the 
Gadl1+/− mice (166, 330, and 750 bp). The sizes of PCR products 
and the primer sequences are summarized in table S5 and Fig. 1E.
Validation of the animal model
The deletion strategy was validated using DNA sequencing, RNA se-
quencing, proteomic analyses, and Western blotting. DNA sequenc-
ing confirmed that exon 7 was absent from the genomic DNA of the 
Gadl1−/− mice. We determined branching scores that reflected each 
exon’s splicing capability using the RNA splicing prediction tool 
SROOGLE (54). This gave a lower splicing score for exon 8 compared 
to exon 9, suggesting that splicing of exon 6 to exon 9 was favored 
over splicing to exon 8. The qRT-PCR data also suggested that the 
Gadl1 mRNA from Gadl1−/− mice was stable. However, sequence 
analysis showed that both exons 7 and 8 were absent from Gadl1 
mRNA in Gadl1−/− mice. An mRNA devoid of exons 7 and 8 is ex-
pected to be stable and produce a truncated protein. Expression and 
purification of mouse GADL1 protein in E. coli were performed as 
described (fig. S2) (24). Site-directed mutagenesis of mouse GADL1 to 
generate a protein lacking exons 7 and 8 (coding protein sequence, 
NHPRFFNQLYAGLDYYSLAARIITEALNPSIYTYEVSPVFLL-
VEEAVLKKMIECVGWKEGDGIFNP) was performed using the 
following primers: GADL1, 5′-TTCAGAACCGCCTCTTCCAC-3′ 
(reverse), 5′-TCCAAGATTTTTCAACCAGC-3′ (foward), 5′-AGA-
AAGCACCGCCGGCTCCT-3′ (forward), 5′-GGATGAGATAGA-
CAGCCTGG-3′ (forward), 5′-TTTCTGTTCATGGGGGTAAT-3′ 
(forward), 5′-TGCGGTATTCGGAATCTTGC-3′ (reverse), 5′-AC-
GCATCGTGGCCGGCATCA-3′ (reverse), 5′-CGATTTCGGCC-
TATTGGTTA-3′ (forward), 5′-TGCACAATCTTCTCGCGCAA-3′ 
(reverse), 5′-ATGGGGGATCATGTAACTCG-3′ (forward), 5′-CTT-
GCTGCAACTCTCTCAGG-3′ (reverse), 5′-CGGATCAAGAGCT-
ACCAACT-3′ (forward), 5′-TAACGAAGCGCTGGCATTGA-3′ 
(reverse), and 5′-GCCTTTGAGTGAGCTGATAC-3′ (forward).
Metabolomic studies using LC-MS
Animals were anesthetized using urethane (250 mg/ml) adminis-
tered by intraperitoneal injection and adjusted to their individual 
weight (1.4 to 1.8 mg/kg). Tissues were perfused with 50 ml of 0.02% 
heparin-saline solution pumped through the heart’s left ventricle be-
fore organ extraction. After dissection, the tissues were flash-frozen 
in liquid nitrogen and stored at −80°C until use. A total of 172 dif-
ferent tissue samples from 41 animals were shipped at −80°C to 
Metabolon Inc. (Durham, NC, USA) for further processing. Male 
and female mice were matched according to genotype and age. Table 2 
shows the list of mice used in the metabolomic study.
All 41 animals were analyzed for brain, SKM, and liver metabo-
lites. A subset of 21 animals (10 Gadl1+/+ and 11 Gadl1−/−, 4.63 and 
4.89 weeks, respectively) were analyzed for OB metabolites. Explor-
atory analyses were performed in the kidney, cerebellum, heart, whole 
blood, and serum from 12-week-old males (seven Gadl1+/+ and seven 
Gadl1−/−). Because of limited capacity of the animal breeding facili-
ty, samples were dissected and shipped in three separate batches, 
with tissues from 10 (5 Gadl1+/+ and 5 Gadl1−/−), 17 (8 Gadl1+/+ and 
9 Gadl1−/−), and 14 (7 Gadl1+/+ and 7 Gadl1−/−) animals, respectively. 
All samples were processed using an identical pipeline.
At the Metabolon Company, samples were prepared using the 
automated Microlab STAR® system from the Hamilton Company. 
To remove protein, dissociate small molecules bound to protein or 
trapped in the precipitated protein matrix, and to recover chemically 
diverse metabolites, proteins were precipitated with methanol un-
der vigorous shaking for 2 min (Glen Mills Geno/Grinder 2000), 
followed by centrifugation. The resulting extract was divided into 
four fractions for analysis using different chromatographic methods. 
Each sample extract was stored overnight under nitrogen before 
preparation for analysis. After that, the samples were reconstituted 
in appropriate solvents (according to the chromatographic method) 
contained a series of standards at fixed concentrations to ensure in-
jection and chromatographic consistency.
Metabolomic analyses were performed through three chromatographic 
methods used that were based on reversed-phase/ultraperformance 
liquid chromatography (UPLC)-MS/MS chromatography with pos-
itive and negative ion mode electrospray ionization (ESI) and one 
chromatographic method using hydrophilic interaction liquid chro-
matography/UPLC-MS/MS with negative ion mode ESI. The columns 
used were Waters UPLC BEH C18 (2.1 mm by 100 mm, 1.7 m) and 
Waters UPLC BEH Amide (2.1 mm by 150 mm, 1.7 m).
Metabolomic analyses were performed at UPLC (Waters ACQUITY) 
coupled to Thermo Fisher Scientific Q Exactive high-resolution/
accurate mass spectrometer interfaced with a heated ESI (HESI-II) 
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The MS analysis alternated between MS and MSn scans using dynam-
ic exclusion. The scan range varied slighted between methods but 
covered 70 to 1000 mass/charge ratio (m/z).
Compounds were identified by comparison to library entries of 
purified standards or recurrent unknown entities. Metabolon main-
tains a library based on authenticated standards that contain the re-
tention time/index (RI), m/z, and chromatographic data (including 
MS/MS spectral data) on all molecules present in the library. Fur-
thermore, biochemical identifications are based on three criteria: 
retention index within a narrow RI window of the proposed identi-
fication, accurate mass match to the library ± 10 parts per million, 
and the MS/MS forward and reverse scores between the experimen-
tal data and authentic standards. The MS/MS scores are based on a 
comparison of the ions present in the experimental spectrum to the 
ions present in the library spectrum.
Normalized areas of each compound were rescaled to set the me-
dian equal to 1. The values obtained for each tissue were used for 
metabolomic analyses with MetaboAnalyst 4.0. Analyses of PLS-DA 
data were normalized using Pareto scaling.
1H-NMR spectroscopy
MAS 1H-NMR spectroscopy was performed using samples (13 to 
20 mg of wet weight) of the OB from 12-week-old male mice of dif-
ferent genotypes Gadl1−/−, Gadl1+/−, and Gadl1+/+. After dissection, 
the samples were stored at −80°C before they were placed in 4-mm 
ZrO2 MAS rotors with 50 l of inserts and analyzed in a 500-MHz 
Bruker instrument at 4°C. Water signal decoupling was achieved by 
presaturation pulses. Each spectrum was recorded at an MAS rate 
of 5 kHz using 256 transients and a 5-s delay between each tran-
sient. To aid comparison, the maximal signal intensities were nor-
malized to the same level for all samples.
1H-MRI of living animals
Animals were anesthetized using 5 to 6% (v/v) sevoflurane (SevoFlo, 
Zoetis Inc., Kalamazoo, MI, USA) mixed with oxygen (200 cm3/min) 
for induction and ~3% for maintenance. During the MRI experi-
ments, the respiration rate was monitored using a pressure sensor 
(SA Instruments, NY, USA). MRI investigations were performed with 
User PharmaScan 70/16 (7 T) scanner from Bruker (Bruker BioSpin 
GmbH, Ettlingen, Germany) using a 72-mm–inner diameter trans-
mit coil together with a mouse brain four-element surface coil array 
for receiving the MR signal. We recorded 13 coronal T2-weighted 
images [slice thickness, 0.5 mm; slice distance, 0.05 mm; field of view 
(FOV), 20 mm by 20 mm; matrix size, 256 by 256] with fat suppres-
sion. The images were recorded with a turbo-RARE sequence [time to 
echo (TE), 38 ms; repetition time (TR), 3200 ms; four averages]. 
The FOV covered the whole brain including the OB. The software 
used with the scanner was ParaVision 6.0.1. Analysis of MR images 
was performed with Fiji ImageJ (version 1.46a, National Institute of 
Health, Bethesda, MD, USA). The OB was manually delineated in 
each image slice, and the number of pixels within each region of 
interest was translated to volume measurement.
RNA purification and qRT-PCR
Total RNA was purified from different tissues from both Gadl1+/+ 
and Gadl1−/− mice using the RNeasy purification kit from QIAGEN 
(#74104; and for muscle tissue, #74704). cDNA was synthesized in 
triplicates from this RNA using a High-Capacity RNA-to-cDNA kit 
(#4387406, Applied Biosystems). qRT-PCR was performed using the 
TaqMan gene expression assay (TaqMan Gene Expression Master Mix, 
#4369016, Applied Biosystems). The TaqMan probes were as follows: 
Mm00520087_m1 (CSAD), Mm01348767_m1 (GADL1, exons 13 to 
14), Mm01341531_m1 (GADL1, exons 3 to 4), Mm01341534_m1 
(GADL1, exons 6 to 7), Mm99999915_g1 [glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH)], and Mm00607939_s1 (-actin). mRNA 
expression for all genotypes was normalized against the housekeep-
ing genes GAPDH and -actin using a variant (2Ct) of the Livak 
method (2−Ct), as described in the real-time PCR applications guide 
from Bio-Rad (55). Values are presented as means and upper 95% 
limit on an ln y scale.
RNA sequencing
RNA sequencing was performed using the TruSeq stranded mRNA 
prep kit from Illumina and an Illumina HiSeq 4000 instrument 
(paired end, 75 bp, ×2 run). Raw data were quality controlled using 
the FastQC tool (available at www.bioinformatics.babraham.ac.uk/
projects/fastqc). Raw reads were aligned to mouse genome M13 using 
HISAT2 (56). Read aligned to coding regions of the genome were 
counted using “FeatureCounts” (57). Normalization and differential 
gene expression were performed using DESeq2 (58). Transcripts from 
27,878 genes at an average were detected. GO enrichment analysis 
was performed using tools “TopGo” and their dependencies in R en-
vironment (version 2.36.0). Biological pathways affected by the Gadl1 
deletion were defined according to GO (27, 28) and the KEGG (27, 59). 
Among the 27,878 mouse genes reliably identified, we further ana-
lyzed up- or down-regulated genes with a log2 fold change either 
less than −1 or greater than +1 and P ≤ 0.05. Heat maps were made 
using ClustVis (59).
Western blotting
We used custom-made affinity-purified sheep antibodies generated 
against purified human GADL1 MBP (maltose-binding protein) fusion 
proteins (J. Hastie, University of Dundee). All the other antibodies were 
purchased from Abcam. The primary antibodies were anti-SOD1 (1:2000; 
CuZn; ab13498), anti-SOD2 (1:1000; Mn; ab68155), and anti-GLR1/
GSR (1:5000; ab16801) prepared in 3% (w/v) bovine serum albumin 
(BSA) in 1× tris-buffered saline (20 mM Trizma base and 150 mM 
NaCl) with 0.1% (v/v) Tween 20 (TBST). Frozen tissue samples (OB, 
SKM, and cerebral cortex) were homogenized in radioimmunopre-
cipitation assay buffer containing a protease inhibitor cocktail. Equal 
amounts of protein (30 mg) were separated by SDS-PAGE and trans-
ferred to a nitrocellulose membrane (Bio-Rad) using a Trans-Blot 
Turbo transfer system (Bio-Rad) according to the manufacturer’s 
protocols. Membranes were blocked with 3% BSA in TBST for 2 hours 
at room temperature before incubation with primary antibodies over-
night at 4°C. The following day, membranes were incubated with 
the secondary antibody, anti-rabbit and goat anti-sheep horseradish 
peroxidase immunoglobulin G H + L (1:10,000; ab6721) (Bio-Rad, 
Hercules, CA), and developed with the enhanced chemiluminescence 
technique using a WesternBright Sirius kit (#K-12043-D20, Advansta) 
on a Gel DocTM XR+ system (Bio-Rad) with Image Lab software 
(version 6.0.1). All blots were normalized against the total protein 
load in a Gadl1+/+ mouse.
Behavioral tests
There were 26 male mice, 13 mice from each genotype (Gadl1+/+ and 
Gadl1−/−) tested for the behavioral experiments. The average age of 
Gadl1+/+ and Gadl1−/− mice was 22.2 and 21.7 weeks, respectively. The order 
of testing of the mice was randomized for each test with the tasks 
following the order, three-chamber social interaction task, open field, 
elevated plus maze, and resident intruder task. Exclusively male mice 
were used to eliminate possible variation caused by the estrous cycle of 
female mice. Upon entry, all mice were provided with a unique tail 
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individually ventilated cage (type 2L, Tecniplast S.p.A., Buguggiate, 
Italy) with an igloo as environmental enrichment and had ad libitum 
access to water and food. Mice were socially isolated before the open 
field task. The mice were housed under a reversed light/dark cycle 
(12:12 hours) in a ventilated cabinet, Scantainer (Scanbur, Karlslunde, 
Denmark), with sunset at 7:30 a.m. at a constant temperature of 24° ± 
1°C. All experimental procedures were approved by the Committee of 
Animal Experiments of the Radboud University Medical Center 
(project number DEC2016-0094), Nijmegen, The Netherlands.
All the behavioral experiments were performed in the dark phase 
under red light conditions in the same experimental room. No 
experiments were performed within the first hour after the light/dark 
transition. All animals were given 1 month to acclimatize to the animal 
housing facility before behavioral testing. EthoVision XT9 software 
(Noldus, Wageningen, The Netherlands) was used for tracking the mice 
and analysis of the videos in the open field and elevated plus maze ex-
periments with the Observer version 11 software (Noldus, Wageningen, 
The Netherlands) used for the assessment of the social interaction and 
resident intruder task experiments. All the behavioral tests were re-
corded using a high-speed (25 frames/s) infrared camera (GigE, Basler 
AG, Ahrensburg, Germany). MediaRecorder (Noldus, Wageningen, 
The Netherlands) was used to record these movies.
Open field
Locomotion activity was quantified in a 55 cm by 55 cm by 36 cm 
activity chamber that was positioned on a flat table with a camera 
directly above the center of the apparatus. The animals were placed 
in the center of the field where locomotion activity was then recorded 
for 5 min. The arena was divided into four quadrants in which the 
connected center points of all quadrants formed the center of the 
field and measured 27.5 cm by 27.5 cm. The total time in the center 
zone, outside the center, and time spent near the walls was measured, 
as well as the frequency of center visits. In addition, the latency to 
leave the center was used as an indication of immobility behavior. 
Reduced frequency of center visits, velocity, and distance traveled 
was used as indications of locomotor activity and anxiety behavior. 
Total distance traveled was measured by tracking movement from 
the center of the mice’s body. The arena was cleaned with 70% alco-
hol between tests. Videotapes of the locomotion activity were exam-
ined using EthoVision XT9 (Noldus, Wageningen, The Netherlands).
Elevated plus maze
The apparatus provided by Noldus consisted of two open arms and 
two closed arms (36 cm by 6 cm, 15-cm-high walls) with a common 
central platform (6 cm2). The apparatus was placed 60 cm above the 
ground. At the start, animals were placed at the junction of the open 
and closed arms with the head facing the closed arms. The elevated 
plus maze was performed in the dark phase under dim light condi-
tions. The time spent in the open and closed arms were examined as 
a time ratio (RT). The RT is the time spent in the open arms (TO) 
divided by total time spent in both closed (TC) and open arms (TO): 
RT = TO/(TO + TC). Furthermore, the frequency of transition be-
tween the arms, the total distance traveled, and velocity was mea-
sured. Between each animal, the maze was cleaned with 70% ethanol 
and dried before testing the next animal.
Resident intruder paradigm
The resident intruder paradigm was performed to assess territorial 
aggression. On each testing day, an unfamiliar C57BL/6J intruder 
mouse was encountered, which was randomly assigned to a resident 
for each interaction. All animals, both resident and intruder, were 
tested once a day. The housing cage of the resident was used as the 
interaction area. A transparent Plexiglas screen was placed in the 
middle of the cage to prevent direct interaction between animals but 
to enable visual, auditory, and olfactory perception. The intruder 
mouse was placed at the other side of the plastic screen for a period 
of 5 min. Hereafter, the screen was removed, and the interaction 
was videotaped for 5 min. After the test, the intruder was removed 
from the cage, and both animals were weighed and checked for 
wounds. The frequency of attacks and bites and the latency to the 
first attack were analyzed manually for all interaction days. An at-
tack latency of 300 s was taken in case no attack occurred within the 
5-min interaction window.
Three-chamber social interaction test
A standard three-chamber task arena (Noldus, Wageningen, The 
Netherlands) was used in a dark room with red overhead lighting. 
During the first 10 min of the test, the test mouse was placed alone 
in the arena to habituate to the new environment. In both the left 
and right chambers, an empty acrylic cylinder with bars was placed. 
After 10 min, an interaction mouse (C57BL/6J mouse, same age as 
test mouse) was placed in a cylinder, randomly in either the left or 
right cylinder. Testing was spread across 2 days with each C57BL/6J 
mouse used maximally four times as an interaction mouse. The order 
of testing was counterbalanced. For 10 min, test mice were allowed 
to investigate the arena with the interaction mouse in it.
Carnosine-related genes in human phenotypes
To conduct the gene-based analyses, we obtained openly available 
summary statistics from GWAS performed in individuals of European 
descent (table S3). We then restricted the data, where possible, to SNPs 
with a minor allele frequency of 1%, with good imputation quality 
(imputation information score, >0.8), and that were represented in more 
than 70% of the total meta-analyzed sample size. We then calculated the 
eight genes of interest’s association with the chosen phenotypes using 
MAGMA (39). The gene-phenotype associations were calculated using 
the individual SNPs’ P values for association with the respective phenotypes. 
SNPs were assigned to a gene if their chromosomal location were 
within the start and end of the gene transcripts (i.e., the standard 
settings of MAGMA). We used the 1000 genomes CEU (Northern 
Europeans from Utah) population as the reference panel to correct 
for linkage disequilibrium.
Variant effect prediction
In total, Ensembl reported 23,292 SNPs in human GADL1, with 78% 
of them being intronic. Among the coding variants, 67% were pre-
sented as missense, 23% as synonymous, 5% as frameshift, 3% as stop 
gained, and 1% as in-frame deletion.
Structural analyses
For comparative protein structure analysis, the structures of mouse 
GADL1 (25) (PDB entry 6enz), human CSAD (PDB entry 2jis), and 
human GAD65 (60) (PDB entries 2okk) were used. To predict the 
binding mode of Glu into GAD65, its structure was re-refined and 
observed to contain the inhibitor chelidonic acid, based on which the 
Glu binding mode can easily be obtained because of the presence of 
two appropriately spaced carboxyl groups. Structures were super-
posed in COOT (61) and visualized in Chimera (62).
Hematoxylin and eosin staining
For the histochemistry studies, the organs were fixed with formalin. 
The samples were paraffin-embedded and sectioned into 40-mm-thick 
slices. For hematoxylin and eosin staining, sections were deparaf-
finized in Tissue-Clear II (2 × 10 min) and rehydrated using 100% 
ethanol (2 × 1 min each), followed by 96% ethanol (1 min) and then 
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Sections were then dipped in 0.2% hematoxylin (Histolab) for 5 min, 
eosin for 1 min, followed by a 5-s wash with ddH2O. The sections 
were then rehydrated in 70% ethanol for 30 s, followed by dipping 
in 96% (2 min) and 100% ethanol (2 × 2 min). Last, the sections were 
dipped in xylene for 2 min, mounted on slides, and coverslipped. 
Hamamatsu slide scanner was used for scanning slides, and Aperio 
software was used to take pictures.
Statistics
All data, unless specified otherwise, are presented as means ± SD. The 
growth curves (Fig. 1, B and C), enzyme activity assay (Fig. 1H), 
NMR (Fig. 3C), MRI, and animal behavior (Fig. 5, A to E) were 
analyzed with unpaired Student’s t test (two-tailed). Statistical 
significance was defined as P ≤ 0.05. Metabolomics data (Fig. 2 and 
fig. S4) were analyzed with unpaired Student’s t test (two- tailed) with 
Welch’s correction. Antioxidant levels (Fig. 4) were analyzed with a 
ratio, paired t test (two-tailed) per experimental setup.
Study approval
The protocol used in this manuscript was approved by the Animal 
Studies Committee, Norwegian Food Safety Authority (Mattilsynet, 
permit number 9468).
SUPPLEMENTARY MATERIAL
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/29/eabb3713/DC1
View/request a protocol for this paper from Bio-protocol.
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